Companies Investors People

Drop to look up

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

Contact
Request a Demo
Request Data Updates
Add a Company

Research

Companies
Investors
People

aVenture

Download App
Pricing
Alternatives

For iPhone and iPad

Resources

Documentation
Use Cases
CLI
MCP
Sitemap

aVenture is an AI-native agentic deep research tool for researching and finding companies and people, and is a high-quality alternative to AlphaSense, CB Insights, Crunchbase, Dealroom, Harmonic, Owler, Perplexity Finance, PitchBook, Preqin, PrivCo, Synaptic, and Tracxn.

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Terms of service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Iterum Therapeutics/

Library

Iterum Therapeutics is a new company record. Its research profile isn't ready yet.

Browse other records

Iterum Therapeutics

Iterum Therapeutics Website, Blog & Press Pages - aVenture Research

Library

iterumtx.comCrawled Nov 1, 2026

Topics

Publication type

Search the library

Content origin

Row density

Product

4 pages

Orlynvah/our-medicines/orlynvah
ORLYNVAH is the first FDA-approved oral penem antibiotic for uncomplicated urinary tract infections in adult women with limited treatment options.
Our Challenge/our-science/our-challenge
Antibiotics have revolutionized medicine. They allow treatment of infections that were once widely fatal; they safeguard surgeries and other procedures that were once unthinkably risky.
Our Promise/our-science/our-promise
Iterum was founded with one over-arching goal: to develop an antibiotic that addresses the growing crisis of multi-drug-resistant pathogens and meets the specific needs of physicians, their patients and other important stakeholders.
Pipeline/our-science/pipeline
The pipeline is currently unavailble, please check back later for further updates.

Blog

2 pages

Posters and presentations/our-science/publications/posters-presentations
Scientific Publications/our-science/publications/scientific-publications
Puttagunta, Sailaja; Aronin, Steven I.; Gupta, Jayanti; Das, Anita F.; Gupta, Kalpana; Dunne, Michael W. NEJM Evidence Volume: 4 Issue: 7

Press

6 pages

External News Links/news/external-news-links
Iterum Therapeutics Announces Filing of Winding Up Petition/press-releases/detail/165/iterum-therapeutics-announces-filing-of-winding-up-petition
Iterum Therapeutics Provides Business Update/press-releases/detail/164/iterum-therapeutics-provides-business-update
--Expanded Market Access and Patent Protection for ORLYNVAH
Iterum Therapeutics Provides Business Update/press-releases/detail/163/iterum-therapeutics-provides-business-update

Careers & Hiring

1 page

Career Opportunities/careers/career-opportunities

Team

2 pages

Board of Directors/about-us/board-of-directors
Dr. Dunne has over 30 years of experience in the life science industry. From 2020 to January 2025, he served as chief medical officer at the Gates Medical Research Institute and previously held roles as chief scientific officer of Iterum Therapeutics and chief medical officer of Durata Therapeutics.
Senior Management/about-us/senior-management
Corey Fishman became CEO in late 2015, when the company was formed. From 2010 to 2015, he served as Chief Financial and Chief Operating Officer of Durata Therapeutics, overseeing finance, administration, manufacturing, business development, and strategy.

About

1 page

Our Company/about-us/our-company

Contact

2 pages

Global Locations/contact/global-locations
200 S Wacker Drive Suite 3100 Chicago, IL 60606 +1 312 778 6070
Partnering Opportunities/contact/partnering-opportunities
Iterum Therapeutics develops anti-infectives to combat multi-drug resistant pathogens, aiming to improve outcomes for serious infections through acquisitions and alliances.

Homepage

1 page

Homepage/
Iterum Therapeutics Limited is dedicated to developing significantly differentiated anti-infectives aimed at combatting MDR pathogens.